Measurements of fractional exhaled nitric oxide in pediatric asthma

Youn-Soo Hahn, MD
Department of Pediatrics, Chungbuk National University College of Medicine, Cheongju, Korea

Exhaled nitric oxide (NO) has been extensively investigated as a noninvasive marker of airway inflammation in asthma. The increased NO expression induced by inflammatory mediators in airways can be monitored easily in exhaled air from asthmatic children. Based on the relationship between the increased NO expression and eosinophilic airway inflammation, fractional exhaled nitric oxide (FeNO) measurements become an important adjunct for the evaluation of asthma. In addition, the availability of portable devices makes it possible to measure FeNO more easily and frequently in the routine pediatric practice. Despite various confounding factors affecting its levels, FeNO can be applicable in diagnosing asthma, monitoring treatment response, evaluating asthma control, and predicting asthma exacerbations. Thus, although pulmonary function tests are the standard tools for objective measurements of asthmatic control, FeNO can broaden the way of asthma monitoring and supplement standard clinical asthma care guidelines.

Key words: Asthma, Breath test, Child, Nitric oxide

Introduction

Although effective asthma control is achieved in the majority of asthmatic patients, a significant numbers of patients still suffer from frequent asthma aggravations which are usually related to airway inflammation\(^1\),\(^2\). Moreover, patients whose asthma is considered under control still have evidences of airway inflammation\(^3\). These findings imply that the routine assessment of airway inflammation is required to ensure the more successful management of asthma. However, treatment of asthma based on sufficient evidences of airway inflammation is not usually instigated even in tertiary referral centers. Instead, the managements of asthmatic patients are usually based on symptoms, pulmonary function tests, assessment of bronchodilator response, and bronchial challenge tests\(^4\). However, symptoms or the results of basic pulmonary function tests may not reflect ongoing airway inflammation\(^5\). For these reasons, the development of monitoring modalities to assess airway inflammation is mandatory. In addition, measurements should be easy to perform, reproducible, and associated with a high degree of acceptance by patients.

Bronchoscopy with biopsy and induced sputum eosinophil count remain the best reliable tools for assessing airway inflammation. However, these monitoring methods are not always applicable as routine procedures because they are time consuming and accompanied by risks. More recently, fractional exhaled nitric oxide (FeNO) has been proposed as means of assessing airway inflammation. High FeNO values above certain cut-point may indicate active eosinophilic airway inflammation and the likelihood of deterioration in asthma control\(^6\). FeNO measurements have also shown potential utility in guiding anti-inflammatory therapy in asthmatic patients\(^7\)-\(^9\). However, the clinical value...
of FeNO measurements may be questioned because FeNO levels are increased in asthma even in mild and asymptomatic conditions. In addition, contribution of the possible sources of NO must be considered when exhaled NO is measured as a marker of airway inflammation. This review focuses on the basic features of exhaled NO and the role of FeNO measurements in pediatric asthma.

**Basic features of NO production**

Nitric oxide (NO) had been considered to be an air pollutant without any specific biological roles. However, NO is involved in a broad range of physiologic and pathologic processes. NO is produced by a variety of cells including airway epithelial cells, vascular endothelial cells, and trafficking inflammatory cells. NO is usually synthesized by NO synthase (NOS) which catalyzes the oxidation of L-arginine to NO and L-citrulline (Fig. 1). Neural NOS (NOS1), inducible NOS (iNOS, NOS2), and endothelial NOS (NOS3) are three different NOS isoenzymes. Constitutive NOS (cNOS) isoenzymes include NOS1 and NOS3, both of which are activated by calcium ions to produce small amounts of NO, which is presumed to play a local regulatory role, such as neurotransmission (NOS1) and regulation of local blood flow (NOS3).

In contrast to cNOS inducing NO production at picomolar concentrations for the transient period, iNOS is able to produce NO in nanomolar concentrations on a continuous basis, reflecting that iNOS is the most important isoenzyme in determining NO output. In addition, iNOS is not constitutively expressed but induced by inflammatory or infectious stimuli and produces NO independent of calcium ion influx. The expression of iNOS is higher in the upper airways than in the lower ones and regulated at the transcriptional level. Expression of iNOS in respiratory epithelium has been shown to be upregulated by Th2 cytokines via the STAT-6 pathway. Asthmatic patients exhibit higher levels of iNOS mRNA expression than healthy controls. The expression of iNOS is decreased after the use of corticosteroid in patients with asthma. Close relationship between FeNO and epithelial iNOS mRNA expression supports that the increased expression of epithelial iNOS is responsible for high FeNO.

**Factors affecting FeNO levels**

High FeNO is observed primarily in atopic asthma, which presents a contrast to normal or near-normal FeNO in nonatopic asthma. In addition, FeNO has been shown to be positively correlated with the level of IgE sensitization and elevated after controlled or natural exposure to allergens. In this regard, inhaled allergens are probably the most important environmental agents enhancing FeNO levels particularly in atopic subjects. Previous studies have shown mixed results concerning interrelationship among asthma, atopy and FeNO. Some studies reported high FeNO mainly confined to atopic children independent of asthma status, while others have found higher FeNO levels in atopic subjects with concomitant asthma than those with atopy alone.

NO can be formed from nonenzymatic NOS-independent sources via reduction of NO metabolites. Consumption of green vegetables with high amounts of nitrate can result in higher levels of NO in exhaled breath. The increase of exhaled NO seems to be proportional to the amount of ingested nitrate and last up to 15 hours after intake. Therefore, it is required to instruct patients to avoid large amount of nitrate-rich food on the day of measurement and encourage a mouthwash as this minimizes the effect of nitrate on FeNO.

Although the results about the effect of physical exercise on FeNO are conflicting, it is better to refrain from physical exercise 1 hour before FeNO measurements to minimize the effect of physical exercise. Cigarette smoking is associated with the reduced levels of FeNO, although FeNO is still high in smokers with asthma. Air pollution such as elevated levels of particulate matter or ozone is associated with the increase of FeNO both in healthy subjects and asthmatics.

Rhinovirus (RV) infection has been known to be a major cause of asthma exacerbation and appears to be associated with systemic eosinophilic activation leading to sputum eosinophilia. RV can induce iNOS expression in the airway epithelium resulting in enhanced NO production. NO response to RV infection is probably beneficial because NO suppress viral replication. Interestingly, asthmatic children with RV infection had lower FeNO than those without RV infection when their asthma was exacerbated, suggesting that RV infection is unlikely to be
involved in Th2-driven iNOS expression.

Corticosteroids can reduce FeNO in asthmatic patients probably by inhibiting the activity of transcriptional factor GATA-3 which regulates interleukin (IL) 4/IL-13 expression in immune cells including Th2 lymphocytes. However, corticosteroids are not able to inhibit epithelial STAT-6 expression which is involved in iNOS expression. Because FeNO appears to be a marker for allergen-induced local airway inflammation, it can monitor the efficacy of different inhaled corticosteroids (ICS) preparations in the treatment of asthma. However, FeNO measurements may be less useful in monitoring asthmatic patients who are frequently exposure to specific allergens because FeNO remains high despite continuous use of ICS in these patients. Leukotriene receptor antagonists can reduce FeNO in asthmatic patients although this effect is less profound than corticosteroids. In contrast, theophylline and chromones are not able to affect the level of FeNO.

The levels of FeNO can be changed by bronchoconstriction and bronchodilation, implying a dependence of FeNO on airway caliber which is related to airway mucosal surface area for NO diffusion. Thus, continuous use of long-acting β₂-agonist in asthmatic patients can result in increase of FeNO.

Despite inconsistent results concerning a sex difference in FeNO levels, there appears to be an association between female sex and lower levels of FeNO. This might be explained by lower endogenous NO production and smaller surface area of the conductive airways in relation to body size in females. Height has been reported to be one of the most independent confounder for FeNO. In a previous study performed in children, an increase from 120 to 180 cm resulted in a doubling of exhaled NO levels, reflecting the greater airway mucosal surface area for NO diffusion as children grow. By the same token, increasing age is associated with an increase of exhaled NO in children. However, the influence of weight or body mass index on FeNO remains unclear because of mixed results in previous studies. Factors and their effects on FeNO are summarized in Table 1.

### Clinical application of FeNO in pediatric asthma

Based on its correlation with bronchial hyperresponsiveness, FeNO may be considered as a screening tool for asthma. Actually, sensitivity and specificity of FeNO measurements have been reported to be acceptable for the diagnosis of asthma in previous clinic-based studies. In particular, FeNO provides significantly higher diagnostic accuracy than lung function tests in discriminating asthmatics from healthy subjects. The power of FeNO in diagnosing asthma can be increased further by the combination of airway hyperresponsiveness and elevated FeNO. However, it is important to remember that low FeNO values do not exclude the diagnosis of asthma because FeNO levels are normal, especially in nonatopic subjects. In addition, because severity or phenotype of airway inflammation may be different

### Methods of FeNO measurements

Exhaled NO is usually measured by chemiluminescence or electrochemical sensing. The chemiluminescence method was first used for detection of exhaled NO in the breath of humans and became the gold standard for FeNO measurements. However, the chemiluminescence-based NO analyzer is expensive and not portable. On the other hand, NO analyzers with electrochemical sensors are hand held devices and relatively cheaper than those based on chemiluminescence. Because there is a good agreement in FeNO levels between both devices, the use of hand held devices becomes increasing.

After inhalation to total lung capacity, patients must exhale immediately into the NO analyzer until a steady plateau is reached. Because FeNO levels are flow dependent, exhalation should be stable at a targeted flow rate of 50 mL/sec and last for 6-10 seconds. Higher exhalation flow rate as well as shorter exhalation time results in FeNO lower than true values. NO scrubber is usually used to ensure that the patients inhale NO-free air. According to the 2005 American Thoracic Society/European Respiratory Society guidelines, FeNO should be measured twice and a third measurement is required if there is a more than 10% difference between first two measurements. In addition, guidelines also recommend avoiding spirometric maneuver before FeNO measurements because this maneuver can lower FeNO. Thus, spirometry should be performed after FeNO measurements. Nasal clip should not be used as it can affect closure of the soft palate, leading to contamination with NO derived from the nasal cavity. In children younger than 5 years, single-breath online measurement is not well standardized since children cannot adequately cooperate. In very young children who cannot maintain a constant flow, FeNO levels are measured during spontaneous breathing, with the exhalation flow adjusted to 50 mL/sec by changing the exhalation resistance.

| Table 1. Factors affecting FeNO levels |
|---------------------------------------|
| Factors increasing FeNO | Factors decreasing FeNO | Factors with uncertain effect |
| Age | Active smoking | Passive smoking |
| Male | Spirometric manoeuvres | Exercise |
| Height | Bronchial provocation | Chromones |
| Atopy | Corticosteroids | Methyloxanthines |
| Asthma | Leukotriene receptor antagonist | |
| Food (nitrate) | Anti-IGE | |

FeNO, fractional exhaled nitric oxide.
among patients with atopic asthma, FeNO levels may be different among these patients. Prior publications have reported reference values for FeNO in healthy children and adolescents. However, because of multiple confounding factors influencing FeNO, normal predictive values for FeNO might be relatively poor and have large confidence intervals. According to the 2011 American Thoracic Society guideline for interpretation of FeNO for clinical applications, asthma with eosinophilic inflammation is less likely in children who have FeNO below 20 ppb. In contrast, FeNO levels higher than 35 ppb in children strongly suggest airway eosinophilia. Thus, discriminating asthma from nonasthmatic conditions in children with intermediate FeNO levels of 20-35 ppb warrants cautious interpretations. For these children with symptoms suggesting asthma, the change of FeNO from the personal best FeNO value may be helpful in interpreting the level of airway inflammation because the intrasubject reproducibility of FeNO levels appears to be good. Based on currently available data, algorithms for interpretation and clinical application of FeNO results can be developed for diagnostic use and ongoing asthma management (Fig. 2).

FeNO correlates with airway eosinophilia in induced sputum, biopsy material, and bronchoalveolar lavage fluid. Therefore, FeNO measurements may be a useful monitoring tool for eosinophilic airway inflammation, without the practical difficulties associated with bronchial biopsy or sputum induction. Furthermore, high FeNO at the time of loss of asthma control and decrease of FeNO after treatment with corticosteroids imply that FeNO is useful not only in predicting asthma exacerbation but in monitoring the response to treatment. The changes in FeNO levels during use of inhaled and oral corticosteroids are rapid and reproducible when repeated. In this regard, FeNO measurements may be helpful in adjusting ICS dose in asthmatic individuals. However, because previous clinical trials reported only equivocal benefits of adding FeNO measurements to usual clinical guidelines for asthma management, it has not been determined that FeNO-based management is beneficial in routine clinical practice. In addition, despite the increase of FeNO prior to asthma exacerbation, evidences are not sufficient enough to suggest that FeNO measurements are able to role as a predictor of asthma exacerbation. Nevertheless, changes in FeNO levels from baseline and individually tailored FeNO values may be both good markers for the upcoming loss of asthma control.

Although asthma aggravation is accompanied by increased symptoms, impaired lung function, and high FeNO levels, there may be discordance among these asthma outcomes. In particular, monitoring of asthma control based on symptoms and normal forced expiratory volume in 1 second might result in under-treatment because persistent airway inflammation does not necessarily manifest itself as symptoms or lung malfunction. High FeNO levels in the absence of symptoms or lung function abnormalities raise the possibility of active eosinophilic airway inflammation and the likelihood of deterioration in asthma control. Thus, in cases of silent airway inflammation, monitoring with FeNO measurements might potentially allow for better targeting and monitoring of anti-inflammatory treatment.

![Fig. 2. Clinical application and interpretation of FeNO levels in pediatric asthma. FeNO, fractional exhaled nitric oxide; EAI, eosinophilic airway inflammation; ICS, inhaled corticosteroids.](http://dx.doi.org/10.3345/kjp.2013.56.10.424)
However, further studies are required to elucidate whether subclinical airway inflammation identified by FeNO measurements needs to be treated.

Conclusions

FeNO is a noninvasive surrogate marker of eosinophilic airway inflammation and responds rapidly to changes in the inflammatory state of the airways. Therefore, combined with other asthma outcomes, FeNO can provide additional information about the ongoing status of asthma. However, although FeNO measurements offer a step forward in the assessment of asthma, the interpretation of FeNO values in patients with asthma needs to be further clarified. Nevertheless, FeNO has a potential to serve as a tool for diagnosing and monitoring pediatric asthma.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

This work was supported by the research grant of the Chungbuk National University in 2012.

References

1. Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Baurer CA, O’Byrne PM, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med 1999;160:594-9.
2. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradling P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-21.
3. Crimi E, Spalonevo A, Neri M, Ind PW, Rossi GA, Brusasco V. Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma. Am J Respir Crit Care Med 1998;157:4-9.
4. National Heart, Lung and Blood Institute. National Asthma Education and Prevention Program, Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full report. 2007 [Internet]. Bethesda: National Heart, Lung and Blood Institute; [cited 2013 Mar 26]. Available from: http://www.nhlbi.nih.gov/guidelines/asthma.
5. Gibson PG. Monitoring the patient with asthma: an evidence-based approach. J Allergy Clin Immunol 2000;106(1 Pt 1):17-26.
6. Lundback B, Dahl R. Assessment of asthma control and its impact on optimal treatment strategy. Allergy 2007;62:611-9.
7. Taylor DR, Pijnenburg MW, Smith AD, De Jongste JC. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 2006;61:817-27.
8. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005;352:2163-73.
9. Shaw DE, Berry MA, Thomas M, Green RH, Brightling CE, Wardlaw AJ, et al. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med 2007;176:2317-7.
10. Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am J Respir Crit Care Med 2005;172:831-6.
11. Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 1993;6:1368-70.
12. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 2001;163:1693-722.
13. Gaston B, Drazen JM, Loscalzo J, Stamler JS. The biology of nitrogen oxides in the airways. Am J Respir Crit Care Med 1994;149(2 Pt 1):538-51.
14. Ricciardolo FL, Sterk PJ, Gaston B, Folkerks G. Nitric oxide in health and disease of the respiratory system. Physiol Rev 2004;84:731-65.
15. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
16. Maniscalco M, Sofia M, Pelaia G. Nitric oxide in upper airways inflammatory diseases. Inflamm Res 2007;56:58-69.
17. Kleinert H, Pautz A, Linker K, Schwarz PM. Regulation of the expression of inducible nitric oxide synthase. Eur J Pharmacol 2004;500:255-66.
18. Guo FH, Comhair SA, Zheng S, Dweik RA, Eissa NT, Thomassen MJ, et al. Molecular mechanisms of increased nitric oxide (NO) in asthma: evidence for transcriptional and post-translational regulation of NO synthesis. J Immunol 2000;164:5970-80.
19. Lane C, Knight D, Burgess S, Franklin P, Horak F, Legg J, et al. Epithelial inducible nitric oxide synthase activity is the major determinant of nitric oxide concentration in exhaled breath. Thorax 2004;59:757-60.
20. Woo SI, Lee JH, Kim H, Kang JW, Sun YH, Hahn YS. Utility of fractional exhaled nitric oxide (FENO) measurements in diagnosing asthma. Respir Med 2012;106:1003-9.
21. Janson C, Kalm-Stephens P, Foucard T, Norback D, Alving K, Nordvall SL. Exhaled nitric oxide levels in school children in relation to IgE sensitisation and window pane condensation. Respir Med 2005;99:1015-21.
22. Ihle E, Gyllfors P, Gustafsson LE, Kumlin M, Dahlen B. Early rise in exhaled nitric oxide and mast cell activation in repeated low-dose allergen challenge. Eur Respir J 2006;27:1152-9.
23. Yao TC, Ou LS, Lee WI, Yeh KW, Chen LC, Huang JL, et al. Exhaled nitric oxide discriminates children with and without allergenic sensitization in a population-based study. Clin Exp Allergy 2011;41:556-64.
24. Sordillo JE, Webb T, Kwan D, Kamel J, Hoffman E, Milton DK, et al. Allergen exposure modifies the relation of sensitization to fraction of exhaled nitric oxide levels in children at risk for allergy and asthma. J Allergy Clin Immunol 2011;127:1165-72.e5.
25. Scott M, Raza A, Karmawa W, Mitchell F, Grundy J, Kurukulaaratchy RJ, et al. Influence of atopy and asthma on exhaled nitric oxide in an unselected birth cohort study. Thorax 2010;65:258-62.
26. Alving K, Malinovschi A. Basic aspects of exhaled nitric oxide: exhaled biomarkers. Eur Respir Monogr 2010;49:1-31.
healthy subjects. Chest 2005;128:2465-70.
28. American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005;171:912-30.
29. Dales R, Wheeler A, Mahmud M, Frescura AM, Smith-Doiron M, Nethery E, et al. The influence of living near roads on spirometry and exhaled nitric oxide in elementary schoolchildren. Environ Health Perspect 2008;116:1423-7.
30. Nickmilder M, de Burbure C, Carboneille S, Dumont X, Bernard A, Derouane A. Increase of exhaled nitric oxide in children exposed to low levels of ambient ozone. J Toxicol Environ Health A 2007;70:270-4.
31. Sanders SP, Proud D, Permutt S, Siekierski ES, Yachechko R, Liu MC. Role of nasal nitric oxide in the resolution of experimental rhinovirus infection. J Allergy Clin Immunol 2004;113:697-702.
32. Leung TF, To MY, Yeung AC, Wong YS, Chan PK. Multiple molecular detection of respiratory pathogens in children with asthma exacerbation. Chest 2010;137:348-54.
33. Barnes PJ. Role of GATA-3 in allergic diseases. Curr Mol Med 2008;8:330-40.
34. Heller NM, Matsukura S, Georas SN, Boothby MR, Stellato C, Schleimer RP. Assessment of signal transducer and activator of transcription 6 as a target of glucocorticoid action in human airway epithelial cells. Clin Exp Allergy 2004;34:1690-700.
35. Bisgaard H, Løland I, Oj JÅ. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 1999;160:1227-31.
36. Lim S, Tomita K, Caramori G, Jatakanon A, Oliver B, Keller A, et al. Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. Am J Respir Crit Care Med 2001;164:273-6.
37. Carrà S, Gagliardi L, Zanconato S, Scollo M, Azzolin N, Zacchello F, et al. Budesonide but not nedocromil sodium reduces exhaled nitric oxide levels in asthmatic children. Respir Med 2001;95:734-9.
38. Buchvald F, Bisgaard H. Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide. Ann Allergy Asthma Immunol 2003;91:309-13.
39. Malmberg LP, Petays T, Haahitel A, Laatikainen T, Jousilahti P, Vartiainen E, et al. Exhaled nitric oxide in healthy nonatopic school-age children: determinants and height-adjusted reference values. Pediatr Pulmonol 2006;41:635-42.
40. Menzies D, Nair A, Lipworth BJ. Portable exhaled nitric oxide measurement: Comparison with the "gold standard" technique. Chest 2007;131:410-4.
41. Silkoff PE, McClean PA, Slutsky AS, Furlott HG, Hoffstein E, Wakita S, et al. Marked flow-dependence of exhaled nitric oxide using a new technique to exclude nasal nitric oxide. Am J Respir Crit Care Med 1997;155:260-7.
42. Buchvald F, Bisgaard H. FeNO measured at fixed exhalation flow rate during controlled tidal breathing in children from the age of 2 yr. Am J Respir Crit Care Med 2001;163(1 Pt 1):699-704.
43. Dupont LJ, Rochette F, Demedts MG, Verleden GM. Exhaled nitric oxide correlates with airway hyperresponsiveness in steroid-naïve patients with mild asthma. Am J Respir Crit Care Med 1998;157(3 Pt 1):894-8.
44. Smith AD, Cowan JO, Filsell S, McLachlan C, Monti-Sheehan G, Jackson P, et al. Diagnosing asthma: comparisons between exhaled nitric oxide measurements and conventional tests. Am J Respir Crit Care Med 2004;169:473-8.
45. Deykin A, Massaro AF, Drazen JM, Israel E. Exhaled nitric oxide as a diagnostic test for asthma: online versus offline techniques and effect of flow rate. Am J Respir Crit Care Med 2002;165:1597-601.
46. Malmberg LP, Petkonen AS, Haahitel T, Turpeinen M. Exhaled nitric oxide rather than lung function distinguishes preschool children with probable asthma. Thorax 2003;58:494-9.
47. Henriksen AH, Lingaaas-Holmen T, Sue-Chu M, Bjerner M. Combined use of exhaled nitric oxide and airway hyperresponsiveness in characterizing asthma in a large population survey. Eur Respir J 2000;15:849-55.
48. Franklin JP, Taplin R, Stick SM. A community study of exhaled nitric oxide in healthy children. Am J Respir Crit Care Med 1999;159:69-73.
49. Baraldi E, Azzolin NM, Cracco A, Zacchello F. Reference values of exhaled nitric oxide for healthy children 6-15 years old. Pediatr Pulmonol 1999;27:54-8.
50. Buchvald F, Baraldi E, Carraro S, Gaston B, De Jongste J, Pijnenburg MW, et al. Measurements of exhaled nitric oxide in healthy subjects age 4 to 17 years. J Allergy Clin Immunol 2005;115:1130-6.
51. Dweik TA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011;184:602-15.
52. Kharitonov SA, Gionio F, Kelly C, Meah S, Barnes PJ. Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. Eur Respir J 2003;21:433-8.
53. Berlyne GS, Parameswaran K, Kamada D, Ethimiaidis A, Hargrave FE. A comparison of exhaled nitric oxide and induced sputum as markers of airway inflammation. J Allergy Clin Immunol 2000;106:638-44.
54. Warke TJ, Fitch PS, Brown V, Taylor R, Lyons JD, Ennis M, et al. Exhaled nitric oxide correlates with airway eosinophils in childhood asthma. Thorax 2002;57:383-7.
55. Zacharasiewicz A, Wilson N, Lex C, Erin EM, Li AM, Hansel T, et al. Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children. Am J Respir Crit Care Med 2005;171:1077-82.
56. Pijnenburg MW, Hofhuis W, Hop WC, De Jongste JC. Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission. Thorax 2005;60:215-8.
57. Silkoff PE, McClean P, Spino M, Erlich L, Slutsky AS, Zamel N. Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients. Chest 2001;119:1322-8.
58. Yoon JY, Woo SJ, Kim H, Sun YH, Hahn YS. Fractional exhaled nitric oxide and forced expiratory flow below 25% and 75% of vital capacity in children with controlled asthma. Korean J Pediatr 2012;55:330-6.
59. Szefler SJ, Mitchell H, Songness CA, Gergen PJ, O’Connor GT, Morgan WJ, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet 2008;372:1065-72.
60. Leuppi JD, Salome CM, Jenkins CR, Anderson SD, Xuan W, Marks GB, et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001;163:406-12.
61. Deykin A, Lazarus SC, Fahy JV, Wechsler ME, Boushey HA, Chinchilli VM, et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol 2005;115:720-7.
62. Jones SL, Kittelson J, Cowan JO, Flannery EM, Hancock RJ, McLa-
chlan CR, et al. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am J Respir Crit Care Med 2001;164:738-43.
63. Scichilone N, Battaglia S, Olivieri D, Bellia V. The role of small airways in monitoring the response to asthma treatment: what is beyond FEV1? Allergy 2009;64:1563-9.
64. Pijnenburg MW, De Jongste JC. Exhaled nitric oxide in childhood asthma: a review. Clin Exp Allergy 2008;38:246-59.